BioCentury
ARTICLE | Company News

Sept. 9 Company Quick Takes: Alexion licenses Japanese rights to Eidos candidate; plus Molecular Partners-Allergan, Horizon, Alnylam

September 14, 2019 12:39 AM UTC

Alexion gets Japanese rights to BridgeBio's ATTR therapy
The Eidos Therapeutics Inc. (NASDAQ:EIDX) subsidiary of BridgeBio Pharma Inc. (NASDAQ:BBIO) granted Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) exclusive rights to develop and commercialize transthyretin-mediated amyloidosis (ATTR) candidate AG10 in Japan. Eidos will receive $25 million up front and $25 million in equity, and is eligible for Japan-based milestones and royalties. Eidos started a Phase III trial in March of the small molecule TTR stabilizer for ATTR cardiomyopathy and plans to start a Phase III trial in ATTR polyneuropathy this half.

FDA, EMA reviewing abicipar for wet AMD
FDA accepted for review a BLA for abicipar pegol from partners Molecular Partners AG (SIX:MOLN) and Allergan plc (NYSE:AGN) to treat neovascular age-related macular degeneration. EMA accepted for review an MAA in August for the designed ankyrin repeat protein that antagonizes VEGF-A. The candidate has a PDUFA date in mid-2020; a decision from the European Commission is expected in 2H20...